Next-generation optimized biotherapeutics - A review and preclinical study

Tadashi Ueda

Research output: Contribution to journalReview articlepeer-review

19 Citations (Scopus)


Biotherapeutics have been clinically used since the 1990s. Recently, next-generation optimized biotherapeutics, which are expected to act on the same molecular target as their predecessors with further properties by antibody-drug conjugation, radiolabeling, PEGylation and glycoconjugation, are on the market. This article reviews recent next-generation optimized biotherapeutics. Moreover, since trials of protein engineering for biotherapeutics have been conducted, these preclinical approaches are also described. This article is part of a Special Issue entitled: Recent advances in molecular engineering of antibody.

Original languageEnglish
Pages (from-to)2053-2057
Number of pages5
JournalBiochimica et Biophysica Acta - Proteins and Proteomics
Issue number11
Publication statusPublished - Nov 2014

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Biophysics
  • Biochemistry
  • Molecular Biology


Dive into the research topics of 'Next-generation optimized biotherapeutics - A review and preclinical study'. Together they form a unique fingerprint.

Cite this